tbuckley/cabot-search huggingface dataset:
Abstract 20263: Improving Symptom Recognition and Symptom Interpretation in Women Who Have Experienced an Acute Coronary Syndrome Event: Results of a Feasibility Study Testing a Nurse-Delivered Educational and Skill Building Intervention
Authors: Leslie L Davis
Journal: Circulation (2016)

Introduction:  The type of symptoms a woman experiences during an acute coronary syndrome (ACS) event influences symptom recognition and interpretation. Women who experience intense, abrupt, “typical” symptoms are more likely to correctly attribute symptoms to a cardiac etiology and seek care in a timely manner. However women with less intense, intermittent, evolving symptoms have greater difficulty recognizing and interpreting symptoms and thus delay seeking medical attention.   Purpose:  A single group pre- post- test design was used to evaluate the feasibility and acceptability of a nurse-delivered intervention designed to improve symptom recognition and interpretation in women with recurrent ACS symptoms.   Method:  Women who had been hospitalized for an ACS event received a personalized education and skill building intervention that was conceptually framed by the investigator’s prior research. Three in-person sessions were followed by 2 phone sessions for reinforcement. Outcomes and acceptability were evaluated at a close out visit approximately 2 months after the index event.   Results:  All but one woman who was approached about the study agreed to participate. Nine of the 10 women enrolled completed all study sessions and data collection within an average of 55 days. Mean knowledge scores increased by 7.4% as measured by the  ACS Response Index . Attitudes towards symptom recognition and help-seeking increased by 2.4 while beliefs towards expectations and actions increased by 3.2. In addition, the women were highly pleased with the intervention with satisfaction scores averaging 1.39 on a 4 point Likert Scale with “1” as “strongly agree” and “4” as “strongly disagree”. All nine women who completed the study stated they would recommend other women join the study.   Conclusion:  The intervention was feasible and acceptable to the women in the study. Results support further testing and refinement of the intervention in a longitudinal randomized control to determine efficacy and sustainability of the intervention.
Global Carbon Cycling on a Heterogeneous Seafloor
Authors: Paul V.R. Snelgrove, Karline Soetaert, Martin Solan, Simon Thrush, Chih-Lin Wei, Roberto Danovaro, Robinson W. Fulweiler, Hiroshi Kitazato, Baban Ingole, Alf Norkko, R. John Parkes, Nils Volkenborn
Journal: Trends in Ecology & Evolution (2017)

Diverse biological communities mediate the transformation, transport, and storage of elements fundamental to life on Earth, including carbon, nitrogen, and oxygen. However, global biogeochemical model outcomes can vary by orders of magnitude, compromising capacity to project realistic ecosystem responses to planetary changes, including ocean productivity and climate. Here, we compare global carbon turnover rates estimated using models grounded in biological versus geochemical theory and argue that the turnover estimates based on each perspective yield divergent outcomes. Importantly, empirical studies that include sedimentary biological activity vary less than those that ignore it. Improving the relevance of model projections and reducing uncertainty associated with the anticipated consequences of global change requires reconciliation of these perspectives, enabling better societal decisions on mitigation and adaptation.
Injury in teenage Gaelic games
Authors: Siobhan O’Connor, Kieran Andrew Moran, Noel McCaffrey, Enda Francis Whyte, Sheree Bekker
Journal: British Journal of Sports Medicine (2017)

Most research examining injury in Gaelic games has focused on elite adult men. Gaelic football and hurling are two of the most popular sports in Ireland, commonly played by teenagers. However, despite their popularity, only one previous study has looked at injuries in teenagers, and this focused on Gaelic footballers only1 and was published back in 1996.



This study followed 292 male teenagers (15.7±0.8 years) who played Gaelic football and hurling over 1 year. Any players …
Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity
Authors: Armin Soave, Roland Dahlem, Hans O. Pinnschmidt, Michael Rink, Jessica Langetepe, Oliver Engel, Luis A. Kluth, Birte Loechelt, Philip Reiss, Sascha A. Ahyai, Margit Fisch
Journal: European Urology (2017)
Immunomonitoring of patients treated with personalized dendritic cell-based vaccine
Authors: L. Fedorova, L Zdrazilova Dubska, K. Pilatova, P. Mudry, P. Mazanek, Z. Pavelka, E. Hlavackova, J. Sterba, L. Flajsarova, R. Demlova, D. Valik
Journal: Annals of Oncology (2017)
Docetaxel followed by temsirolimus in suppression of mTOR pathway.
Authors: Chao H Huang, Peter J. Van Veldhuizen, Ayten Gadashova, Stephen K. Williamson, Faris Farassati
Journal: Journal of Clinical Oncology (2012)

e13535 Background: Mammalian target of rapamicin(mTOR) is a downstream regulatory protein of the PI3K/Akt signal transduction pathway. This is a common pathway for a several cell surface receptors including IGFR (Insulin-like Growth Factor Receptor) and EGFR (Epidermal Growth Factor Receptor). The activation of these receptors through PI3K/Akt pathway is essential in cell proliferation, angiogenesis and anti-apoptosis process. Several therapeutic agents that inhibit these receptors have shown to be active in the treatment of diverse types of cancers. Docetaxel (D) is commonly used in the treatment of lung cancer. We demonstrated previously that the sequence of D followed by mTOR inhibition using temsirolimus (T) in lung cancer cell lines (LCCL) had synergistic effect in suppressing cell proliferation compared with T→D. The exact mechanism of this effect is unknown. We studied the expression of mTOR, Raptor and PI3K in these cell lines treated in different time points to investigate the activity of this pathway when using these sequences of drug treatment. Methods: Adenocarcinoma LCCL H2122 and H1437 were plated and exposed to temsirolimus 1000nM and docetaxel 100nM. The cell viability was measured by optical density (OD) at 24, 48 and 72h. We tested the sequence of D treated for 24h followed by addition of T and the reverse in both LCCL. We then prepared cell lysate at 24h, 48h and 72h time points and studied the expression of mTOR, Raptor and PI3K by western blot using antibody obtained from Cell Signaling. Results: The sequence of D→T had increased suppression of mTOR, Raptor and PI3K at 48 and 72 hours compared with the opposite sequence of T→D. Conclusions: The combination of D → T seems to have synergistic suppression of mTOR and PI3K pathway in 2 LCCL compared with opposite sequence. Further studies in animal models using this sequence and confirmation of mTOR suppression may help determine if this is a feasible combination in the treatment of lung cancer.
Erratum: The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue–resident regulatory T cells
Authors: Ajithkumar Vasanthakumar, Kazuyo Moro, Annie Xin, Yang Liao, Renee Gloury, Shimpei Kawamoto, Sidonia Fagarasan, Lisa A Mielke, Shoukat Afshar-Sterle, Seth L Masters, Susumu Nakae, Hirohisa Saito, John M Wentworth, Peng Li, Wei Liao, Warren J Leonard, Gordon K Smyth, Wei Shi, Stephen L Nutt, Shigeo Koyasu, Axel Kallies
Journal: Nature Immunology (2015)
Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Authors: J-P Machiels, C-J Yen, L. Licitra, D. Rischin, J. Waldron, B. Burtness, V. Gregoire, Y.G. Tao, J. Yorio, S. Aksoy, S. Ikeda, R-L Hong, J.Y. Ge, H. Brown, B. Bidadi, L. Siu
Journal: Annals of Oncology (2017)
Abstract 33: CEACAM1 blockade increases NK cell cytotoxicity in head and neck squamous cell carcinoma
Authors: Kenric Tam, Yunqin Lee, David Schoppy, John B. Sunwoo
Journal: Clinical Cancer Research (2017)

Abstract In conjunction with advances made in cytotoxic chemotherapy, radiation, and surgery, immunotherapy has emerged in recent years as a promising fourth modality of treatment for head and neck squamous cell carcinoma (HNSCC). Cetuximab, an anti-EGFR antibody, is now routinely used as an adjunct to radiation therapy and in the recurrent/metastatic setting following treatment failure with concurrent cisplatin and radiation. Understanding the fundamental mechanisms by which HNSCC evades the immune system will aid the development of new therapies and strategies to augment an antitumor immune response. Carcinoembryonic-antigen-related cell-adhesion molecule 1 (CEACAM1) is a cell surface receptor that is expressed on HNSCC cells, as well as on lymphocytes, such as NK cells. Overexpression of CEACAM1 in HNSCC has been associated with a poor prognosis, higher clinical stage, recurrence, and lymph node metastasis. A phase I trial (NCT02346955) of an anti-CEACAM1 antibody is currently underway for a variety of non-HNSCC malignancies. We demonstrate that in mice inoculated with TUBO-EGFR, a murine cancer cell line, treatment with an anti-CEACAM1 antibody rescues NK cell effector function from exhaustion resulting in reduced tumor growth and enhanced antibody-dependent cell-mediated cytotoxicity. The addition of Cetuximab has an additive effect and results in additional tumor shrinkage. Thus, these data indicate that CEACAM1 is a novel checkpoint molecule on NK cells. CEACAM1 is also expressed on tumor cells themselves; its expression in HNSCC is associated with suppression of NK cell cytotoxicity. In vitro co-incubation of NK cells with PCI-13, a human HNSCC cell line, results in IFNγ-mediated upregulation of CEACAM1 on the tumor cells. IFNγ-exposed cells are more resistant to NK cytotoxicity compared to untreated cells, suggesting that immune pressure induces upregulation of NK inhibitors. Importantly, CEACAM1+ NK cells have decreased cytotoxicity against HNSCC tumor cells compared to CEACAM1- NK cells, but the addition of an anti-CEACAM1 antibody restores NK cell effector function. Together, these data indicate that CEACAM1 acts as a checkpoint molecule and that a blocking antibody against CEACAM1 releases its immunosuppressive effects and could serve as a novel immunotherapy for HNSCC. Citation Format: Kenric Tam, Yunqin Lee, David Schoppy, John B. Sunwoo. CEACAM1 blockade increases NK cell cytotoxicity in head and neck squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; April 23-25, 2017; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(23_Suppl):Abstract nr 33.
Erratum: Corrigendum: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease
Authors: K S Lang, M Recher, T Junt, A A Navarini, N L Harris, S Freigang, B Odermatt, C Conrad, L M Ittner, S Bauer, S A Luther, S Uematsu, S Akira, H Hengartner, R M Zinkernagel
Journal: Nature Medicine (2005)
Emergency Department Opioid Misuse Diagnoses Increasing in Adolescents and Young Adults
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14175: Cytotoxin-associated Gene-A-seropositivity and Interleukin-1 Polymorphisms Influence the Development and Recurrence of Acute Coronary Syndrome
Authors: Noriaki Tabata, Takayoshi Yamashita, Tomonori Akasaka, Daisuke Sueta, Yuichiro Arima, Tomokazu Ikemoto, Seiji Hokimoto
Journal: Circulation (2016)

Background: Cytotoxin-accociated Gene-A (CagA)-seropositivity produced by Helicobacter pylori (HP) is associated vascular atherosclerosis as well as carcinogenesis. Pro-inflammatory interleukin-1 (...
A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen
Authors: Guanshu Liu, Sangeeta Ray Banerjee, Xing Yang, Nirbhay Yadav, Ala Lisok, Anna Jablonska, Jiadi Xu, Yuguo Li, Martin G. Pomper, Peter van Zijl
Journal: Nature Biomedical Engineering (2017)
Data-Driven Mammography Screening Practices
Authors: David Seidenwurm, Jon Breslau
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
Authors: Juraj Koska, Aramesh Saremi, Scott Howell, Gideon Bahn, Barbora De Courten, Henry Ginsberg, Paul J. Beisswenger, Peter D. Reaven
Journal: Diabetes Care (2017)

OBJECTIVE The goal of this study was to determine whether plasma levels of advanced glycation end products (AGE) and oxidation products (OP) predict the incidence of cardiovascular disease (CVD) in type 2 diabetes. RESEARCH DESIGN AND METHODS Five specific AGE (methylglyoxal hydroimidazolone, carboxymethyl lysine, carboxyethyl lysine, 3-deoxyglucosone hydroimidazolone, and glyoxal hydroimidazolone) and two OP (2-aminoadipic acid and methionine sulfoxide [MetSO]) were measured at baseline in two intensive glucose-lowering studies: 1) a subcohort of the Veterans Affairs Diabetes Trial (VADT) (n = 445) and 2) a nested case-control subgroup from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (n = 271). RESULTS Increased levels of several AGE and OP were associated with older age, decreased kidney function, previous CVD, and longer diabetes duration, but not with hemoglobin A1c. In the VADT, increased risk of incident CVD events (n = 107) was associated with lower MetSO after adjusting for age, race/ethnicity, sex, prior CVD event, kidney function, treatment assignment, and diabetes duration (hazard ratio [HR] 0.53; 95% CI 0.28–0.99; P = 0.047). Individuals with both low MetSO and high 3-deoxyglucosone hydroimidazolone concentrations were at highest risk for CVD (HR 1.70; P = 0.01). In the ACCORD study, those with incident CVD events (n = 136) had lower MetSO (by 14%; P = 0.007) and higher glyoxal hydroimidazolone and carboxymethyl lysine (by 18% and 15%, respectively; P = 0.04 for both); however, only the difference in MetSO remained significant after adjustment for prior CVD event (P = 0.002). CONCLUSIONS Lower levels of MetSO and higher levels of select AGE are associated with increased incident CVD and may help account for the limited benefit of intensive glucose lowering in type 2 diabetes.
Gene therapy boosts factor IX activity and reduces bleeding events in patients with haemophilia B, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

A single treatment with a vector carrying an engineered factor IX transgene achieved a sustained increase in the clotting factor’s coagulant activity in patients with haemophilia B and reduced bleeding events, results from a small open label trial showed.1

Haemophilia B results from a deficiency or dysfunction of coagulation factor IX, which leads to recurrent spontaneous haemarthrosis. It is currently treated with exogenous factor IX that is infused one to three times each week to prevent bleeding or given on demand when bleeding occurs. But this causes peaks and troughs of coagulant activity …
Carbon footprinting in health systems: one small step towards planetary health
Authors: Tim Taylor, Phil Mackie
Journal: The Lancet Planetary Health (2017)

Climate change is without doubt one of the major threats facing public health. While we are already experiencing extreme weather events worldwide, the longer term impacts on health will include increased heat-related mortality, increased food-borne disease, and increased risk of vector-borne and water-borne disease.1 Coupled with increasing—and mobile—populations and antimicrobial resistance, the pressures on health systems will be substantial. Is it surprising then that the Paris Agreement formally linked human and planetary health so clearly and sought to harness leadership from the health sector to achieve robust change? It is in this light that efforts to assess the carbon footprinting of different elements of health care are needed.
The prospective MammaPrint MINT (Multi-Institutional Neo-adjuvant Therapy) study.
Authors: Charles E. Cox, Peter William Blumencranz, Ruben A. Saez, Robert Wesolowski, Lisette Stork, Femke De Snoo, Jessica Gibson, Nicole Howard, Eli Avisar
Journal: Journal of Clinical Oncology (2013)

TPS11122 Background: Patients with locally advanced breast cancer (LABC) are often treated with neo-adjuvant chemotherapy to reduce the size of the tumor before definitive surgery. Complete pathologic Response (pCR) predicts better long term outcome. Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic and predictive tools for early breast cancer. This study is designed to test the ability of molecular profiling, as well as traditional pathologic and clinical prognostic factors to predict responsiveness to neo-adjuvant chemotherapy in patients with LABC. Methods: Women ≥ 18 yrs with histologically-proven invasive breast cancer T2(≥3.5cm)-T4,N0M0 or T2-T4N1M0, with measurable disease, adequate bone marrow reserves and normal renal and hepatic function who signed informed consent are enrolled. Axillary lymph nodes will be staged according to protocol. MammaPrint risk profile, BluePrint molecular subtyping profile, TargetPrint ER, PR and HER2 single gene readout, and the 56-gene TheraPrint Research Gene Panel will be analysed using the whole genome expression array. Patients will receive neo-adjuvant chemotherapy treatment according to protocol. Response will be measured by centrally assessed Residual Cancer Burden (RCB). Objectives are: (1) To determine the predictive power of MammaPrint and BluePrint for sensitivity to neo-adjuvant chemotherapy as measured by pCR. (2) To identify and/or validate predictive gene expression profiles of clinical response or resistance to neo-adjuvant chemotherapy. (3) To compare TargetPrint ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment. (4) To identify correlations between TheraPrint and response to neo-adjuvant chemotherapy. (5) To compare BluePrint molecular subtype with IHC-based subtype classification. To achieve a difference of 20% in chemotherapy sensitivity for patients stratified by MammaPrint, a total of 226 samples is needed (significance level 0.05 and power of 0.90). So far 45 patients have been enrolled from multiple institutions. Clinical trial information: NCT01501487.
Effect of Nasal Continuous Positive Airway Pressure on Infants With Meconium Aspiration Syndrome
Authors: Aakash Pandita, Srinivas Murki, Tejo Pratap Oleti, Baswaraj Tandur, Sai Kiran, Sachin Narkhede, Amrut Prajapati
Journal: JAMA Pediatrics (2017)

Nasal continuous positive airway pressure (NCPAP) as a primary respiratory therapy in meconium aspiration syndrome (MAS) has not been studied extensively. Nasal continuous positive airway pressure, when applied in newborns with MAS, may resolve atelectasis by sufficiently expanding partially obstructed small airways and stabilizing the collapsing terminal airways to enhance oxygen exchange.To compare NCPAP vs standard care in neonates with moderate to severe respiratory failure due to MAS in reducing the need for invasive ventilation.This multicenter open-label, parallel-group (1:1 ratio) randomized clinical trial was conducted from August 5, 2014, to May 26, 2016. Data were collected from 3 tertiary care neonatal intensive care units. All infants admitted with respiratory distress, defined as Downe score greater than 4 and peripheral capillary oxygen saturation less than 90%, were assessed for study eligibility if the chest radiograph was suggestive of MAS and they met the other inclusion criteria: gestation longer than 35 weeks, a birth weight greater than 2000 g, and born through meconium-stained amniotic fluid.Infants were randomly assigned to either NCPAP or standard care (5-10 L/min hood oxygen).The primary outcome was the need for mechanical ventilation in the first 7 days of life.After excluding 14 infants, 67 infants were randomized to bubble NCPAP and 68 infants to standard care. Baseline characteristics were similar between the 2 groups. Infants randomized to the bubble NCPAP group needed mechanical ventilation less frequently in the first 7 days of life compared with standard care (2 [3.0%] vs 17 [25.0%]); odds ratio, 0.09; 95% CI, 0.02-0.43; P = .002). The need for surfactant (3 [4.5%] vs 11 [16.2%]; odds ratio, 0.24; 95% CI, 0.05-0.87) and culture-positive sepsis (4 [6.0%] vs 13 [19.0%]; odds ratio, 0.28; 95% CI, 0.09-0.93) were higher in the standard care group. There was an increased duration of oxygen therapy (median [interquartile range], 45.5 [28.0-78.3] vs 26 [20.0-48.0] hours; P = .001) in the standard care group. In the NCPAP group vs standard care group, incidence of persistent pulmonary hypertension (9 [13%] vs 19 [28%]; odds ratio, 0.42; 95% CI, 0.17-1.01) and duration of hospital stay (median [interquartile range], 5.0 [4.0-8.8] vs 4.0 [4.0-6.0] days; P = .14) were similar.Bubble NCPAP in comparison with standard care for infants with MAS reduces the need for mechanical ventilation in the first 7 days of life.Clinical Trial Registry, India Identifier: CTRI/2015/03/005631.